Profile data is unavailable for this security.
About the company
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer.
- Revenue in USD (TTM)14.60k
- Net income in USD-13.25m
- Incorporated1994
- Employees12.00
- LocationKazia Therapeutics LtdThree International Towers Level 24, 300 Barangaroo AvenueSYDNEY 2000AustraliaAUS
- Phone+61 29472-4100
- Fax+61 29476-0388
- Websitehttps://www.kaziatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Longeveron Inc | 709.00k | -22.21m | 8.20m | 23.00 | -- | 4.03 | -- | 11.57 | -10.18 | -10.18 | 0.3262 | 0.4245 | 0.0359 | -- | 4.31 | 30,826.09 | -108.45 | -63.15 | -139.35 | -75.68 | 31.17 | 33.70 | -3,020.17 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Glucose Health Inc | 1.11m | -456.46k | 8.25m | 2.00 | -- | 8.70 | -- | 7.41 | -0.033 | -0.033 | 0.0803 | 0.0561 | -- | -- | -- | -- | -- | -86.94 | -- | -153.95 | 47.19 | 40.68 | -31.99 | -56.93 | 313.11 | -- | 0.00 | -- | 98.39 | 24.94 | 16.87 | -- | -- | -- |
| Notable Labs Ltd | 310.00k | -11.26m | 8.30m | 16.00 | -- | 0.549 | -- | 26.76 | -3.08 | -3.08 | 0.0939 | 1.68 | 0.0126 | -- | -- | 19,375.00 | -45.79 | -52.02 | -56.70 | -62.09 | 36.45 | 60.19 | -3,633.55 | -3,636.93 | -- | -- | 0.0221 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| NuCana PLC (ADR) | 0.00 | -34.51m | 8.37m | 25.00 | -- | 0.4503 | -- | -- | -410.22 | -410.22 | 0.00 | 8.79 | 0.00 | -- | -- | 0.00 | -64.21 | -41.01 | -102.19 | -48.07 | -- | -- | -- | -- | -- | -77.43 | 0.0259 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Virios Therapeutics Inc | 0.00 | -5.30m | 8.70m | 4.00 | -- | -- | -- | -- | -0.283 | -0.283 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Energy Finders Inc | 4.06m | -2.92m | 8.73m | 46.00 | -- | -- | -- | 2.15 | -0.272 | -0.272 | 1.52 | 3.04 | -- | -- | -- | 88,304.35 | -- | -- | -- | -- | 27.45 | -- | -71.79 | -- | 0.6706 | -12.57 | 0.564 | -- | -- | -- | -- | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 14.60k | -13.25m | 8.83m | 12.00 | -- | 0.9789 | -- | 604.48 | -0.8034 | -0.8034 | 0.0008 | 0.342 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Biofrontera Inc | 34.07m | -20.13m | 9.36m | 85.00 | -- | 0.5826 | -- | 0.2748 | -15.19 | -15.19 | 24.30 | 3.16 | 0.8646 | 1.93 | 5.42 | 400,858.80 | -51.08 | -- | -101.07 | -- | 48.80 | -- | -59.08 | -- | 0.6727 | -2.71 | 0.4489 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Vaccinex Inc | 570.00k | -20.25m | 9.41m | 37.00 | -- | -- | -- | 16.51 | -63.98 | -63.98 | 1.23 | -2.59 | 0.0982 | -- | 1.00 | 15,405.41 | -348.91 | -262.29 | -1,283.74 | -- | -- | -- | -3,552.81 | -4,257.17 | -- | -59.75 | -- | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
| Inhibikase Therapeutics Inc | 260.50k | -19.03m | 9.52m | 8.00 | -- | 0.8284 | -- | 36.55 | -3.62 | -3.62 | 0.0489 | 1.77 | 0.0132 | -- | 13.06 | 32,562.50 | -96.49 | -66.49 | -117.79 | -85.55 | -- | -- | -7,304.76 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| 22nd Century Group Inc | 32.20m | -64.68m | 9.55m | 64.00 | -- | -- | -- | 0.2967 | -49.97 | -116.47 | 29.49 | -3.09 | 0.4531 | 5.70 | 8.81 | 503,187.50 | -76.94 | -46.78 | -105.06 | -54.18 | -27.00 | -2.11 | -169.81 | -107.95 | 0.4766 | -4.62 | 2.39 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Endexx Corp | 4.64m | 6.93m | 9.57m | -- | 1.42 | -- | 1.61 | 2.06 | 0.0133 | 0.0133 | 0.0091 | -0.0255 | 0.6773 | 4.37 | 13.54 | -- | 86.51 | -- | -- | -- | 28.73 | -- | 127.74 | -- | 0.0664 | -- | -- | -- | 228.66 | -- | 28.26 | -- | -- | -- |
| Eterna Therapeutics Inc | 68.00k | -21.68m | 9.58m | 8.00 | -- | 4.29 | -- | 140.83 | -4.08 | -4.08 | 0.0128 | 0.4128 | 0.0019 | -- | 0.0988 | 8,500.00 | -60.69 | -169.05 | -75.78 | -223.00 | -173.53 | -- | -31,864.71 | -682.61 | -- | -33.19 | 0.7813 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
